Corcept Therapeutics Incorporated
Every calculator, already run for CORT
Open the full toolkit →You have the numbers on CORT. Get the argument.
A written report on which of these readings actually decide the outcome for Corcept Therapeutics Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering CORTAnalyst Price Target Disagreement for Corcept Therapeutics Incorporated
Wall Street's bull case implies +44% from the current price; the bear case implies -56%. A 100% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-ass…
CORT — frequently asked
Is CORT a buy right now?
Wall Street's consensus rating on Corcept Therapeutics Incorporated is Buy across 4 analysts, with a mean price target of $135.25 (+18% vs. the current $114.47). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is CORT overvalued?
CORT trades at 254.4x trailing earnings, against a DCF fair value of $24 per share. The current price implies 26% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Corcept Therapeutics Incorporated?
Analysts covering Corcept Therapeutics Incorporated (CORT) range from a bear-case target of $50.00 to a bull-case high of $165.00, with a mean consensus target of $135.25 across 4 analysts. The spread of $115.00 (100% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Corcept Therapeutics Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Corcept Therapeutics Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CORT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Corcept Therapeutics Incorporated, in minutes. 3 free reports included with every account — no credit card required.